What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The pivotal ROSELLA phase 3 trial demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to nab-paclitaxel alone, with hazard ratios of 0.70 and 0.65 respectively. These results indicate a clear clinical advantage over the standard of care, fulfilling the criteria for an A+ rating.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses or incremental cost/QALY estimates were found in the available documentation. The absence of any economic model or budget impact analysis indicates that the therapy cannot be deemed cost-effective, leading to a C rating.
Is there quality-of-life evidence payers weigh? — Quality of life
There is a notable absence of HRQoL data in the ROSELLA trial documentation. No specific HRQoL instruments or utility values were reported, which raises concerns about the treatment’s impact on patients’ overall well-being. This lack of evidence leads to a B rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of relacorilant + nab-paclitaxel shows a manageable incidence of adverse effects, with serious adverse reactions occurring in 35% of patients. The detailed reporting of adverse events and the presence of monitoring requirements suggest a very good tolerability, justifying an A+ rating.
Was the drug compared against what payers expect? — Comparator Selection
The ROSELLA trial compared relacorilant + nab-paclitaxel against nab-paclitaxel monotherapy, which is a relevant comparator in the context of platinum-resistant ovarian cancer. This direct comparison supports an A rating, as it aligns with current treatment practices.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial enrolled a representative population of patients with platinum-resistant ovarian cancer who had received prior bevacizumab. While there are some limitations regarding generalizability due to prior treatment requirements, the core population is well-defined, supporting an A rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with manageable adjustments, as it does not require significant changes to current practices. The regimen’s compatibility with existing protocols supports an A rating.
Are the wider system costs understood? — Resource Use and Cost Implications
While the regimen specifics are provided, there is a lack of data on direct costs and implementation costs. This raises concerns about the overall resource burden, leading to a B rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a phase 3 randomized trial with dual primary endpoints and prespecified analyses. While there are some limitations due to the open-label design, the overall quality of evidence supports an A rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are areas of uncertainty, particularly regarding post-marketing commitments and the absence of cost-effectiveness analyses. While some contextual factors are addressed, the overall uncertainty leads to a B+ rating.
